Sentence examples for benign prostatic disease from inspiring English sources

The characteristics of the patients with benign prostatic disease and prostate cancer are shown in Table 1 > -wrap-foot>.

The relationship between circulating concentrations of interleukin-6 and C-reactive protein in patients with benign prostatic disease and prostate cancer is shown in Figure 1.

The correlation coefficients for patients with benign prostatic disease and prostate cancer were rs=0.632, P<0.001 and rs=0.663, P<0.001, respectively.

As the distribution of interleukin-6 and C-reactive protein concentrations was skewed, they were logarithmically transformed to illustrate their relationship in patients with benign prostatic disease and prostate cancer.

White et al. [ 35] used a glycomic approach to characterize glycans cleaved from prostate-specific antigen and prostatic acid phosphatase purified from seminal samples representative of normal controls, benign prostatic disease, and prostate cancer patients.

Histological sections of 12 paraffin wax-embedded prostate cancers and 12 non-malignant prostate tissues from specimens of benign prostatic disease without malignancy were obtained from Department of Pathology, University of Liverpool, UK.

Subjects with other malignancies, hormonal disorders or benign prostatic diseases and men with the prostate specific antigen >= 4 ng/ml were excluded from the control group.

However, considering different categories of controls, we observed that PSA and UCF-DNA integrity had the same low specificity in benign prostatic diseases (39%), confirming that the PSA test has a high number of false positive results [ 3], especially when benign conditions such as prostatitis or adenomas are present.

Approximately 50% of patients with advanced prostate cancer have elevated levels of serum IL-6 in comparison with men with normal prostates, benign prostatic hyperplasia, prostatitis and localised disease (Twillie et al, 1995; Drachenberg et al, 1999).

The expression of TGF-β1 is elevated in most carcinomas and many proliferative diseases including benign prostatic hyperplasia, prostate cancer and prostatitis [9], [10], [11], [12].

With informed consent prostatic tissue was obtained from males undergoing treatment for malignant (CaP) or non-malignant benign prostatic hyperplasia (BPH) disease.